GUTS תחזית צמיחת רווחים לשנה הבאה fractyl.com
Fractyl Health, Inc. (GUTS) is implementing proprietary hydroablation to combat diabetes, creating an alternative to injections. The expected EPS growth rate for the coming year confirms this potential, with the figure standing at -25.10. However, popular weight-loss drugs and the complexities of clinical trials are exerting pressure. High testing costs and strict FDA oversight protect the niche from new entrants.
GUTS (fractyl.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
Fractyl Health, Inc. (GUTS) is achieving a breakthrough in endocrinology by developing metabolic engineering methods to cure type 2 diabetes without injections. This forward-looking earnings per share (EPS) growth forecast consolidates expert expectations for EPS dynamics, reflecting market confidence in the commercialization of these innovations. The positive trend in the forward EPS growth forecast confirms the fundamental price stability and the business's scaling potential.
